2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine;hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine;hydrochloride
• 化学式: C16H18ClN3
• 分子量: 287.79
• InChiKey: XZHPFZGIABQTNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.03
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• TRANSNASAL COMPOSITION HAVING IMMEDIATE ACTION AND HIGH ABSORBABILITY
  申请人：Translational Research, Ltd.

  公开号：EP1785145A1

  公开（公告）日：2007-05-16

  Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.

  用于鼻内给药的粉末状组合物由非肽类/非蛋白质类药物和作为载体的结晶纤维素聚合体（具有特定的核状颗粒直径）组成，可使药物快速发挥作用并具有高吸收性。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH IMPROVED PHARMACOKINETICS
  申请人：Shin Nippon Biomedical Laboratories, Ltd.

  公开号：EP2429495A1

  公开（公告）日：2012-03-21
• DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
  申请人：The Scripps Research Institute

  公开号：EP2675893A1

  公开（公告）日：2013-12-25
• Compositions that Enable Rapid-Acting and Highly Absorptive Intranasal Administration
  申请人：Nagata Ryoichi

  公开号：US20080260848A1

  公开（公告）日：2008-10-23

  Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.